The BAHCC1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the BAHCC1 gene in a well-established human cervical cancer cell line. This polyclonal product provides a mixed cell population harboring heterogeneous knockout alleles, enabling robust loss-of-function studies without requiring clonal isolation. The BAHCC1 gene encodes a chromatin-associated transcriptional regulator implicated in polycomb repressive complex 2 (PRC2)-mediated gene silencing, making these cells an essential tool for investigating epigenetic mechanisms in cervical cancer biology.
HeLa cells, derived from a 31-year-old female with cervical adenocarcinoma, are one of the most extensively used human cell lines in biomedical research. This cell line is HPV-18 positive, aneuploid, and serves as a classic epithelial tumor model for studying cervical carcinogenesis, viral oncogenesis, and tumor biology. The combination of HPV-18 oncogene expression and aneuploidy recapitulates key features of cervical cancer, providing a physiologically relevant context for examining BAHCC1 function in chromatin remodeling and gene repression.
BAHCC1 is a chromatin-associated protein that putatively interacts with core components of the polycomb repressive complex 2 (PRC2), including EZH2, SUZ12, and EED. Through recognition of the trimethylated lysine-27 of histone H3 (H3K27me3) mark, BAHCC1 is thought to facilitate transcriptional repression of target genes. This interaction positions BAHCC1 downstream of PRC2 catalytic activity or as a cofactor stabilizing the complex at silenced loci, thereby influencing chromatin remodeling and gene expression programs associated with cell proliferation and differentiation. Disruption of BAHCC1 enables dissection of its role in PRC2-dependent and PRC2-independent silencing mechanisms, offering insights into the hierarchy of polycomb-mediated gene regulation.
In cervical cancer, deregulation of epigenetic modifiers, including components of the PRC2 complex, contributes to aberrant gene silencing and malignant progression. HeLa cells, harboring HPV-18 oncogenes, exhibit altered chromatin landscapes and rely on PRC2 activity for maintenance of the transformed phenotype. The BAHCC1 knockout HeLa polyclonal cells thus offer a powerful isogenic model to study the functional interplay between BAHCC1 and PRC2 in a cervical adenocarcinoma background, enabling researchers to investigate how loss of this putative co-regulator affects histone modification patterns, gene expression, and tumorigenic properties. This model is particularly valuable for examining context-dependent transcriptional repression mechanisms in HPV-positive cancers.
These polyclonal knockout cells are suitable for a wide range of functional investigations, including chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) and co-immunoprecipitation (co-IP) to assess changes in H3K27me3 deposition and BAHCC1-associated protein complexes upon gene disruption. Global transcriptional profiling via RNA-seq and targeted expression analysis by RT-qPCR can reveal downstream genes derepressed following loss of BAHCC1, while proliferation assays provide insights into its impact on cell growth. Additionally, western blotting confirms target protein depletion, and rescue experiments with BAHCC1 mutants can validate specific functional domains. By integrating these approaches, the BAHCC1 Knockout HeLa Polyclonal Cells serve as a versatile platform for deciphering epigenetic regulatory networks in cervical cancer and for evaluating potential therapeutic targets within the polycomb repressive complex signaling axis. For further technical details and lot-specific validation data, please contact Ascent Research.
